Stockscreener 앱 받기
6.83
1.49%
0.10
시간 외 거래:
6.83
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Why is Fulcrum Therapeutics Inc. stock attracting strong analyst attentionMassive stock growth - jammulinksnews.com
Is Fulcrum Therapeutics Inc. a good long term investmentTremendous portfolio expansion - jammulinksnews.com
What is Fulcrum Therapeutics Inc. company’s growth strategyUnlock powerful market insights for success - jammulinksnews.com
Fulcrum Therapeutics shares slide 17% after sickle cell trial results - MSN
Technical signs of recovery in Fulcrum Therapeutics Inc.Price Spike Prediction for Active Traders - Newser
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Entry Optimization Guide with Volume Analysis - Newser
When is Fulcrum Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - jammulinksnews.com
How strong is Fulcrum Therapeutics Inc. company’s balance sheetMaximize returns with timely market signals - jammulinksnews.com
How does Fulcrum Therapeutics Inc. generate profit in a changing economyHigh-profit capital plays - jammulinksnews.com
What institutional investors are buying Fulcrum Therapeutics Inc. stockInvest smarter with cutting-edge analytics - jammulinksnews.com
Is Fulcrum Therapeutics Inc. stock overvalued or undervaluedAccess exclusive market insights for free - jammulinksnews.com
FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald - Defense World
Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningTrend Confirmation Scanner with Entry Focus - Newser
Will Fulcrum Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsOversold Opportunity Scanner with RSI Data - Newser
Q3 Earnings Forecast for FULC Issued By Leerink Partnrs - Defense World
Is Fulcrum Therapeutics Inc. stock ready for a breakoutReal-Time AI Entry Forecast Generator - Newser
Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Portfolio Diversification Stock Ideas - Newser
Are Bears Losing Grip on Fulcrum Therapeutics Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it
What catalysts could drive Fulcrum Therapeutics Inc. stock higher in 2025Market Forecast Tracker For Smart Trading - jammulinksnews.com
How to interpret RSI for Fulcrum Therapeutics Inc. stockTen-Year Sector Performance and Summary Analysis - Newser
What is the risk reward ratio of investing in Fulcrum Therapeutics Inc. stockPre Market Insights For Beginners - jammulinksnews.com
How many analysts rate Fulcrum Therapeutics Inc. as a “Buy”Wealth Building Picks That Work - jammulinksnews.com
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.29 Consensus Target Price from Brokerages - Defense World
Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsAI Trading Suggestions With Accuracy Focus Released - metal.it
Fulcrum Therapeutics stock price target raised to $5 at RBC Capital - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Buy at HC Wainwright - Defense World
Is Fulcrum Therapeutics Inc. building a consolidation baseTrend Following Ideas with Volume Confirmation - Newser
Published on: 2025-07-30 02:00:45 - Newser
Fulcrum Therapeutics 2024 Q2 Earnings Strong Turnaround with Net Income Swing of 333% - AInvest
H.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data - Investing.com Canada
Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment - TipRanks
HC Wainwright Raises Fulcrum Therapeutics' PT to $12 from $4 - AInvest
Fulcrum Therapeutics Inc. Stock Fails to Break Resistance Traders ReactDaily Smart Money Movement Monitor Activated - beatles.ru
Fulcrum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Fulcrum Therapeutics Plunges 29.58% on PIONEER Trial Results - AInvest
Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 1c - StreetInsider
Fulcrum Therapeutics stock falls after sickle cell disease trial results By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics stock falls after sickle cell disease trial results - Investing.com
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics Reports Positive Results from Phase 1b PIONEER Trial of Pociredir for Sickle Cell Disease - Quiver Quantitative
Fulcrum Therapeutics reports Q2 results, pociredir trial data - StreetInsider
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - Yahoo Finance
Breakthrough Sickle Cell Treatment Achieves 44% Success Rate in Latest Clinical Trial Data - Stock Titan
Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionDaily Investment Ideas with Market Insight - Newser
Published on: 2025-07-29 13:21:15 - beatles.ru
0.93%
0.15%
자본화:
|
볼륨(24시간):